Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

20 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Development and validation of a gene expression-based Breast Cancer Purity Score.
Barreca M, Dugo M, Galbardi B, Győrffy B; NA-PHER2 consortium; NeoTRIP consortium; Valagussa P, Besozzi D, Viale G, Bianchini G, Gianni L, Callari M. Barreca M, et al. Among authors: galbardi b. NPJ Precis Oncol. 2024 Oct 24;8(1):242. doi: 10.1038/s41698-024-00730-7. NPJ Precis Oncol. 2024. PMID: 39448787 Free PMC article.
The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer.
Dugo M, Huang CS, Egle D, Bermejo B, Zamagni C, Seitz RS, Nielsen TJ, Thill M, Antón-Torres A, Russo S, Ciruelos EM, Schweitzer BL, Ross DT, Galbardi B, Greil R, Semiglazov V, Gyorffy B, Colleoni M, Kelly CM, Mariani G, Del Mastro L, Blasi O, Callari M, Pusztai L, Valagussa P, Viale G, Gianni L, Bianchini G. Dugo M, et al. Among authors: galbardi b. Clin Cancer Res. 2024 Nov 1;30(21):4900-4909. doi: 10.1158/1078-0432.CCR-24-0149. Clin Cancer Res. 2024. PMID: 39308141 Free PMC article. Clinical Trial.
Pan-cancer analysis of antibody-drug conjugate targets and putative predictors of treatment response.
Bosi C, Bartha Á, Galbardi B, Notini G, Naldini MM, Licata L, Viale G, Mariani M, Pistilli B, Ali HR, André F, Piras M, Callari M, Barreca M, Locatelli A, Viganò L, Criscitiello C, Pusztai L, Curigliano G, Győrffy B, Dugo M, Bianchini G. Bosi C, et al. Among authors: galbardi b. Eur J Cancer. 2023 Dec;195:113379. doi: 10.1016/j.ejca.2023.113379. Epub 2023 Oct 11. Eur J Cancer. 2023. PMID: 37913680 Free article.
Feasibility and long-term outcomes of surgery for primary thoracic synovial sarcoma.
Pieropan S, Mercier O, Mitilian D, Pradère P, Fabre D, Ion DI, Mir O, Galbardi B, Thomas De Montpreville V, Fadel E. Pieropan S, et al. Among authors: galbardi b. Interact Cardiovasc Thorac Surg. 2022 Sep 9;35(4):ivac238. doi: 10.1093/icvts/ivac238. Interact Cardiovasc Thorac Surg. 2022. PMID: 36066443 Free PMC article.
Predictive Role of CD36 Expression in HER2-Positive Breast Cancer Patients Receiving Neoadjuvant Trastuzumab.
Ligorio F, Di Cosimo S, Verderio P, Ciniselli CM, Pizzamiglio S, Castagnoli L, Dugo M, Galbardi B, Salgado R, Loi S, Michiels S, Triulzi T, Tagliabue E, El-Abed S, Izquierdo M, de Azambuja E, Nuciforo P, Huober J, Moscetti L, Janni W, Coccia-Portugal MA, Corsetto PA, Belfiore A, Lorenzini D, Daidone MG, Vingiani A, Gianni L, Pupa SM, Bianchini G, Pruneri G, Vernieri C. Ligorio F, et al. Among authors: galbardi b. J Natl Cancer Inst. 2022 Dec 8;114(12):1720-1727. doi: 10.1093/jnci/djac126. J Natl Cancer Inst. 2022. PMID: 35789270
Modulation of the Estrogen/erbB2 Receptors Cross-talk by CDK4/6 Inhibition Triggers Sustained Senescence in Estrogen Receptor- and ErbB2-positive Breast Cancer.
Viganò L, Locatelli A, Ulisse A, Galbardi B, Dugo M, Tosi D, Tacchetti C, Daniele T, Győrffy B, Sica L, Macchini M, Zambetti M, Zambelli S, Bianchini G, Gianni L. Viganò L, et al. Among authors: galbardi b. Clin Cancer Res. 2022 May 13;28(10):2167-2179. doi: 10.1158/1078-0432.CCR-21-3185. Clin Cancer Res. 2022. PMID: 35254385 Free PMC article. Clinical Trial.
The TRAR gene classifier to predict response to neoadjuvant therapy in HER2-positive and ER-positive breast cancer patients: an explorative analysis from the NeoSphere trial.
Triulzi T, Bianchini G, Di Cosimo S, Pienkowski T, Im YH, Bianchi GV, Galbardi B, Dugo M, De Cecco L, Tseng LM, Liu MC, Bermejo B, Semiglazov V, Viale G, de la Haba-Rodriguez J, Oh DY, Poirier B, Valagussa P, Gianni L, Tagliabue E. Triulzi T, et al. Among authors: galbardi b. Mol Oncol. 2022 Jun;16(12):2355-2366. doi: 10.1002/1878-0261.13141. Epub 2021 Dec 17. Mol Oncol. 2022. PMID: 34816585 Free PMC article.
Preclinical and Clinical Characterization of Fibroblast-derived Neuregulin-1 on Trastuzumab and Pertuzumab Activity in HER2-positive Breast Cancer.
Guardia C, Bianchini G, Arpí-LLucià O, Menendez S, Casadevall D, Galbardi B, Dugo M, Servitja S, Montero JC, Soria-Jiménez L, Sabbaghi M, Peña R, Madoz-Gúrpide J, Lloveras B, Lluch A, Eroles P, Arribas J, Pandiella A, Gianni L, Rojo F, Rovira A, Albanell J. Guardia C, et al. Among authors: galbardi b. Clin Cancer Res. 2021 Sep 15;27(18):5096-5108. doi: 10.1158/1078-0432.CCR-20-2915. Epub 2021 Aug 12. Clin Cancer Res. 2021. PMID: 34385295
20 results